Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurochem Gets Second FDA “Approvable” Letter For Kiacta

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.

You may also be interested in...



Neurochem Will Resubmit Kiacta After Conducting New Phase III Study

Company pulls NDA for AA amyloidosis therapy, currently "approvable" at FDA, while it conducts a new trial.

Neurochem Will Resubmit Kiacta After Conducting New Phase III Study

Company pulls NDA for AA amyloidosis therapy, currently "approvable" at FDA, while it conducts a new trial.

Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline

Firm will move a tramiprosate pro-drug into preclinical development and launch Alzhemed as a nutraceutical, in line with a new business model.

Related Content

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel